These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35919584)
1. A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes. Attwa MW; Abdelhameed AS; Alsaif NA; Kadi AA; AlRabiah H RSC Adv; 2022 Jul; 12(31):20387-20394. PubMed ID: 35919584 [TBL] [Abstract][Full Text] [Related]
2. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes. Mostafa GAE; Kadi AA; AlMasoud N; Attwa MW; Al-Shakliah NS; AlRabiah H J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122806. PubMed ID: 34325312 [TBL] [Abstract][Full Text] [Related]
3. Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS. Attwa MW; Al-Shakliah NS; AlRabiah H; Kadi AA; Abdelhameed AS J Pharm Biomed Anal; 2022 Mar; 211():114626. PubMed ID: 35123331 [TBL] [Abstract][Full Text] [Related]
4. Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation. Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA Molecules; 2023 Mar; 28(5):. PubMed ID: 36903565 [TBL] [Abstract][Full Text] [Related]
5. LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. Attwa MW; Abdelhameed AS; Kadi AA Drug Des Devel Ther; 2021; 15():3915-3925. PubMed ID: 34552321 [TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes. Attwa MW; AlRabiah H; Kadi AA Molecules; 2023 Mar; 28(5):. PubMed ID: 36903615 [TBL] [Abstract][Full Text] [Related]
7. Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method. Attwa MW; AlRabiah H; Mostafa GAE; Bakheit AH; Kadi AA Molecules; 2023 Mar; 28(6):. PubMed ID: 36985590 [TBL] [Abstract][Full Text] [Related]
8. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies. Attwa MW; Kadi AA; Abdelhameed AS; Alhazmi HA Drug Des Devel Ther; 2020; 14():783-793. PubMed ID: 32158196 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening. Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896209 [TBL] [Abstract][Full Text] [Related]
10. A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. Attwa MW; Darwish HW; Al-Shakliah NS; Kadi AA Molecules; 2021 May; 26(9):. PubMed ID: 34063139 [TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay. Attwa MW; Abdelhameed AS; Al-Shakliah NS; Kadi AA Drug Des Devel Ther; 2020; 14():4439-4449. PubMed ID: 33122888 [TBL] [Abstract][Full Text] [Related]
12. A novel bioanalytical method for the quantification of pemigatinib in rat plasma by UPLC-MS/MS. Weng Q; Tan W; Yu RY; Xu RA; Chen Y J Pharm Biomed Anal; 2021 Aug; 202():114137. PubMed ID: 34015593 [TBL] [Abstract][Full Text] [Related]
13. Assessment of the Attwa MW; AlRabiah H; Abdelhameed AS; Kadi AA Front Chem; 2024; 12():1323738. PubMed ID: 39391832 [TBL] [Abstract][Full Text] [Related]
14. Pemigatinib: First Approval. Hoy SM Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305 [TBL] [Abstract][Full Text] [Related]
15. An ultra-fast ultra-high-performance liquid chromatography-tandem mass spectrometry method for estimating the in vitro metabolic stability of palbociclib in human liver microsomes: In silico study for metabolic lability, absorption, distribution, metabolism, and excretion features, and DEREK alerts screening. Attwa MW; Abdelhameed AS; Kadi AA J Sep Sci; 2024 Aug; 47(15):e2400346. PubMed ID: 39087624 [TBL] [Abstract][Full Text] [Related]
16. Ultra-fast UPLC-MS/MS approach for estimating X-376 in human liver microsomes: Evaluation of metabolic stability via in silico software and in vitro analysis. Attwa MW; Abdelhameed AS; Kadi AA J Pharmacol Toxicol Methods; 2024; 128():107540. PubMed ID: 38996943 [TBL] [Abstract][Full Text] [Related]
17. Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability. Abdelhameed AS; Kadi AA; Attwa MW; AlRabiah H PLoS One; 2019; 14(4):e0214598. PubMed ID: 30947315 [TBL] [Abstract][Full Text] [Related]
18. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance. Tang LWT; Chan ECY J Pharm Biomed Anal; 2022 May; 214():114731. PubMed ID: 35325798 [TBL] [Abstract][Full Text] [Related]
19. A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation. Abdelhameed AS; Attwa MW; Al-Shaklia NS; Kadi AA R Soc Open Sci; 2019 Jun; 6(6):190434. PubMed ID: 31312501 [TBL] [Abstract][Full Text] [Related]
20. Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma. Attwa MW; Kadi AA; Darwish HW; Abdelhameed AS RSC Adv; 2018 Nov; 8(70):40387-40394. PubMed ID: 35558213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]